Company news

Catalyst Pharmaceuticals, Inc. news in 2026

Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

June 30, 2026

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

May 11, 2026

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

May 7, 2026

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

May 7, 2026

Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

April 28, 2026

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

March 5, 2026

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

February 25, 2026

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference

February 24, 2026

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

February 11, 2026

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

January 8, 2026

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)

January 4, 2026

Calls in 2026

Decks in 2026